BARTOLOME MARÍ, ANGEL A. LOPEZ-GONZALEZ, FELIX GRASES, MATIAS TOMÁS-SALVÁ, ADRIAN RODRIGUEZ

Urinary phytate concentration and risk of fracture determined by the FRAX index in a group of postmenopausal women

Background/aim: This study was designed to evaluate the relationship between urinary phytate concentration and risk of fracture at10 years, determined by using the FRAX model, in women who had undergone menopause within 5 years of the time of enrollment.Materials and methods: Of the 212 postmenopausal women evaluated, 69 were excluded because they had urinary phytate concentrationsbetween 0.51 and 0.99 mg/L. Of the remaining 143 women, 91 had low (≤0.50 mg/L) and 52 had high (≥1.0 mg/L) urinary phytateconcentrations. The 10-year risk of fracture was calculated by using the FRAX model.Results: The risks of major osteoporotic fracture and hip fracture were higher in women with low urinary phytate levels (P < 0.001 inboth cases). Evaluation of the risk of hip fracture in women with and without risk factors for osteoporosis (e.g., tobacco, alcohol, anddrug consumption) and according to urinary phytate concentrations indicated that, among women with no risk factors, those with lowand high urinary phytate levels had a range of risks of 0%–0.6% and 0%–0.3%, respectively (P = 0.098). Moreover, among women with atleast one risk factor, those with low and high urinary phytate had a range of risks of 0.1%–0.8% and 0.1%–0.4%, respectively (P = 0.002).Similar results were observed when the risks of major osteoporotic fracture were analyzed.Conclusion: These results indicate the relationship of phytate with the risks of major osteoporotic fracture and hip fracture, with thesedifferences being more marked in women with risk factors for osteoporosis. From this study follows the importance of the consumptionof phytate-rich products (nuts, legumes, whole cereals) to protect against the risk of fracture in 10 years, mainly in women with riskfactors for osteoporosis.

PDF

___

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795.
2. González-Macías J, del Pino-Montes J, Olmos JM, Nogués X. Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral (3.ª versión actualizada 2014). Revista Clínica Española 2015; 215: 515-526 (in Spanish).
3. Institute for Clinical System Improvement. Diagnosis and Treatment of Osteoporosis. 6th ed. Bloomington, MN, USA: Institute for Clinical System Improvement; 2008.
4. Brown JP, Fortier M, Frame H, Lalonde A, Papaioannou A, Senikas V, Yuen CK; Osteoporosis Guidelines Committee. Canadian Consensus Conference on Osteoporosis, 2006 update. J Obstet Gynaecol Can 2006; 28: S95-S112.
5. Scottish Intercollegiate Guidelines Network. Management of Osteoporosis. A National Clinical Guideline. Edinburgh, UK: Scottish Intercollegiate Guidelines Network; 2003.
6. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397.
7. Schlemmer U, Frolich W, Prieto RM, Grases F. Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res 2009; 53: S330-S735.
8. Grases F, Simonet BM, Prieto RM, March JG. Variation of InsP(4), InsP(5) and InsP(6) levels in tissues and biological fluids depending on dietary phytate. J Nutr Biochem 2001; 12: 595-601.
9. Grases F, Simonet BM, Vucenik I, Prieto RM, Costa-Bauzá A, March JG, Shamsuddin AM. Absorption and excretion of orally administered inositol hexaphosphate (IP6 or phytate) in humans. Biofactors 2001; 15: 53-61.
10. Grases F, Isern B, Sanchis P, Perello J, Torres JJ, Costa-Bauza A. Phytate acts as an inhibitor in formation of renal calculi. Front Biosci 2007; 12: 2580-2587.
11. Grases F, Prieto RM, Simonet BM, March JG. Phytate prevents tissue calcifications in female rats. Biofactors 2000; 11: 171- 177.
12. Grases F, Santiago C, Simonet BM, Costa-Bauza A. Sialolithiasis: mechanism of calculi formation and etiologic factors. Clin Chim Acta 2003; 334: 131-136.
13. Grases F, Perelló J, Sanchis P, Isern B, Prieto RM, Costa-Bauzá A, Santiago C, Ferragut ML, Frontera G. Anticalculus effect of a triclosan mouthwash containing phytate: a double-blind, randomized, three-period crossover trial. J Periodontal Res 2009; 44: 616-621.
14. Grases F, Sanchis P, Perello J, Isern B, Prieto RM, FernandezPalomeque C, Saus C. Phytate reduces age-related cardiovascular calcification. Front Biosci 2008; 13: 7115-7122.
15. Grases F, Sanchis P, Costa-Bauzá A, Bonnin O, Isern B, Perelló J, Prieto RM. Phytate inhibits bovine pericardium calcification in vitro. Cardiovasc Pathol 2008; 17: 139-145.
16. Fernández-Palomeque C, Grau A, Perelló J, Sanchis P, Isern B, Prieto RM, Costa-Bauzá A, Caldés OJ, Bonnin O, Garcia-Raja A et al. Relationship between urinary level of phytate and valvular calcification in an elderly population: a cross-sectional study. PLoS One 2015;10: e0136560.
17. Lopez-Gonzalez AA, Grases F, Roca P, Mari B, Vicente-Herrero MT, Costa-Bauza A. Phytate (myo-inositol hexaphosphate) and risk factors for osteoporosis. J Med Food 2008; 11: 747- 752.
18. Lopez-Gonzalez AA, Grases F, Perello J, Tur F, Costa-Bauza A, Monroy N, Mari B, Vicente-Herrero T. Phytate levels and bone parameters: a retrospective pilot clinical trial. Front Biosci (Elite Ed) 2010; 2: 1093-1098.
19. Grases F, Sanchis P, Prieto RM, Perello J, Lopez-Gonzalez AA. Effect of tetracalcium dimagnesium phytate on bone characteristics in ovariectomized rats. J Med Food 2010; 13: 1301- 1306.
20. López-González AA, Grases F, Monroy N, Marí B, VicenteHerrero MT, Tur F, Perelló J. Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women. Eur J Nutr 2013; 52: 717-726.
21. Grases F, Perelló J, Isern B, Prieto RM. Determination of myoinositol hexakisphosphate (phytate) in urine by inductively coupled plasma atomic emission spectrometry. Anal Chim Acta 2004; 510: 41-43.
22. University of Sheffield. FRAX Calculation Tool. Sheffield, UK: University of Sheffield; 2018. Available online at http://www. shef.ac.uk/FRAX/tool.aspx?country=4.
23. Grases F, Ramis M, Costa-Bauza A. Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates. Urol Res 2000; 28: 136-140.
24. Addison WN, McKee MD. Inositol hexakisphosphate inhibits mineralization of MC3T3-E1 osteoblast cultures. Bone 2010; 46: 1100-1107.
25. Arriero Mdel M, Ramis JM, Perello J, Monjo M. Inositol hexakisphosphate inhibits osteoclastogenesis on RAW 264.7 cells and human primary osteoclasts. PLoS One 2012; 7: e43187.